# Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD

> **NCT03834766** · PHASE3 · COMPLETED · sponsor: **Tris Pharma, Inc.** · enrollment: 130 (actual)

## Conditions studied

- ADHD

## Interventions

- **DRUG:** AMPH ER Tab 5, 10, 15 and 20 mg
- **DRUG:** AMPH ER Tab Matching Placebo 5, 10, 15 and 20 mg

## Key facts

- **NCT ID:** NCT03834766
- **Lead sponsor:** Tris Pharma, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-06
- **Primary completion:** 2019-10-19
- **Final completion:** 2019-10-19
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2023-11-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03834766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03834766, "Amphetamine Extended-Release Tablets in the Treatment of Adults With ADHD". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03834766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*